Liquidia Corporation
LQDA
Clasificación en acciones
#4682
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Precio por acción
$36.17
Capitalización bursátil
$3.24B
Cambio (1 día)
5.98%
Cambio (1 año)
48.00%
País
US
Comercio Liquidia Corporation (LQDA)
Categoría
Healthcare
Ratio P/B de Liquidia Corporation (LQDA)
Ratio P/B al October 2026 TTM: 15.46
Según los informes financieros más recientes y el precio de las acciones de Liquidia Corporation, el ratio P/B actual (TTM) es 15.46. Al final de 2023, el ratio P/B era 16.53.
Historial del ratio P/B de Liquidia Corporation desde 2016 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 15.46 | 29.07% |
| 2024 | 11.98 | -27.55% |
| 2023 | 16.53 | 284.98% |
| 2022 | 4.29 | -649.51% |
| 2021 | -0.78 | -155.57% |
| 2020 | 1.41 | -37.80% |
| 2019 | 2.26 | -72.77% |
| 2018 | 8.30 | -393.49% |
| 2017 | -2.83 | -45.85% |
| 2016 | -5.22 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 3.8424 | -75.15% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 17.3539 | 12.24% |
US
|
